文献速递外周动脉疾病

生物合成移植物Omniflow II在慢性肢体威胁性缺血中的多中心注册研究

Biosynthetic Prosthesis Omniflow II in Chronic-Limb Threatening Ischemia: Results of the Multicenter National Registry Omni-Femoropopliteal.
PubMed 文献 · Ann Vasc Surg · 2026-01-14

本研究为2019至2023年开展的国家级前瞻性多中心注册研究,纳入83例接受股腘动脉旁路术的慢性肢体威胁性缺血(CLTI)患者,评估Omniflow II生物合成移植物的通畅率、再干预、并发症及保肢率。结论认为该移植物在CLTI患者中中期结果良好,尤其膝下吻合的旁路通畅率较好,可作为无自体静脉患者的替代选择。

要点

  • Omniflow II在CLTI股腘旁路中2年二期通畅率膝上组71%、膝下组70%。
  • 膝下吻合的旁路通畅率优于膝上吻合,支持其作为无自体静脉患者的替代选择。

核心结论

  • Omniflow II生物合成移植物在CLTI患者股腘旁路术中显示良好的中期通畅率和保肢效果,尤其膝下吻合旁路通畅率较好,可作为无自体静脉患者的替代选择。

研究设计与样本

  • 国家级前瞻性多中心注册研究,2019至2023年纳入83例接受Omniflow II股腘旁路术的CLTI患者,膝上组28例,膝下组55例,平均随访18±12个月。

主要发现

  • 2年一期通畅率膝上组51%、膝下组60%,二期通畅率膝上组71%、膝下组70%。
  • 移植物感染需取出者4例(4.8%),动脉瘤样退变1例(1.2%)且无需手术干预。

临床怎么用

  • 对于缺乏合适自体静脉的CLTI患者,Omniflow II可作为股腘旁路移植的替代选择,尤其膝下吻合时中期通畅率较好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic limb-threatening ischemia (CLTI) represents a severe condition associated with high morbidity and mortality, particularly in patients lacking optimal autologous vein. The prevalence of CLTI accentuates the need to find a different conduit. Biological prostheses have emerged as a viable alternative given the limitations of conventional synthetic grafts for the treatment of CLTI patients. The objective of this study was to evaluate the clinical outcomes, patency, and limb salvage rates of the Omniflow II biosynthetic prosthesis (LeMaitre Vascular, Inc., Burlington, MA) in infrainguinal bypass procedures among CLTI patients. METHODS: This was a national, prospective, multicenter study conducted between 2019 and 2023, including patients with CLTI who underwent femoropopliteal bypass using Omniflow II. Patency, reintervention, postoperative complications (including graft degeneration or infection), and limb salvage rates were assessed. RESULTS: A total of 83 patients were included: 28 underwent above-knee femoropopliteal bypass (AK group), and 55 underwent below-knee femoropopliteal bypass (BK group). The mean follow-up was 18 ± 12 months. At 2 years, primary and secondary patency rates were 51% and 71% in the AK group, and 60% and 70% in the BK group, respectively. An amputation-free survival rate of 81,4% at 2 years was observed. Prosthetic infection requiring explantation occurred in 4 patients (4.8%), and aneurysmal degeneration was reported in one case (1.2%) that did not require surgical intervention. CONCLUSION: The use of Omniflow II in patients with CLTI demonstrated favorable midterm outcomes, particularly regarding patency in bypasses with distal infragenicular anastomosis. These findings support its consideration as an alternative in patients without available autologous vein.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Baturone A, Serrano FJ, Camblor LA, et al. Biosynthetic Prosthesis Omniflow II in Chronic-Limb Threatening Ischemia: Results of the Multicenter National Registry Omni-Femoropopliteal. Ann Vasc Surg. 2026. PMID: 41544849. doi:10.1016/j.avsg.2025.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。